Table 3.
Group | Treatment | No. | Visible tumors |
Microscopic changes |
||||
---|---|---|---|---|---|---|---|---|
Incidence (%) | Number | Volume (cm3) | No. of dysplasia | Incidence of SCC | No. of SCC | |||
2A | Negative control | 5 | - | - | - | - | - | - |
2B | DMBA | 25 | 96.0 (24/25) | 3.70±2.79 | 7.64±18.67 | 1.52±1.40 | 96.0 (24/25) | 3.00±2.28 |
2C | DMBA + 0.5mM garcinol | 21 | 81.0 (17/21) | 2.18±1.70** | 0.90±1.80* | 1.37±1.30 | 81.0 (17/21) | 1.63±1.34** |
2D | DMBA + 5mM garcinol | 23 | 82.6 (19/23) | 2.45±2.01* | 0.52±1.44* | 1.06±0.25 | 87.0 (20/23) | 1.56±1.04** |
2E | DMBA + 50mM garcinol | 25 | 80.0 (20/25) | 2.13±1.75** | 0.58±1.41* | 0.85±0.18* | 84.0 (21/25) | 1.23±0.81** |
P <0.05 as compared with Group 2B
P<0.01 as compared with Group 2B.